Company intelligence / Profile preview
PNB Vesper Life Sciences
- Ownership
- Private
- Development stage
- Phase 3
Overview
PNB Vesper has six New Chemical Entities under development, with two molecules in clinical phases and four in preclinical stages. Lead assets target serious unmet medical needs such as IBD, pain disorders, several cancers, and opioid tolerance. The most advanced program is reported to be at Phase 3 for IBD; other programs are at various earlier clinical or preclinical stages. The company has received Indian FDA approval for trials and collaborates globally for R&D activities.
- Therapeutic areas
- OncologyInfectious DiseasesPsychiatryRheumatologyGastroenterologyWomen's Health
- Modalities
- Small molecules (NCEs)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on PNB Vesper Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNB Vesper Life Sciences.